2013•International Journal of HematologyRequires access

Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate

Yoo Jin Lee, Joon Ho Moon, Ho Cheol Shin, Jong Won Seo, Seo Ae Han, Sang Kyeong Seo, Sang Kyun Sohn

Open publisher page 17 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 17 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Essential thrombocythemia, JAK2 V617F, Imatinib mesylate, Medicine, Hematology, Internal medicine, Imatinib, Anagrelide

Back to paper search Browse research topics Original source

Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate — Research Paper | ScholarLens